US2086186A
(en)
|
1933-10-10 |
1937-07-06 |
Us Rubber Co |
Treatment of rubber
|
SU50906A1
(ru)
|
1935-12-20 |
1936-11-30 |
А.И. Бурляев |
Веретено дл пр дильных машин
|
GB1435721A
(en)
|
1972-05-18 |
1976-05-12 |
Lilly Industries Ltd |
Benzoxazole derivatives
|
JPS6192592A
(ja)
|
1984-10-12 |
1986-05-10 |
Norin Suisansyo Shokuhin Sogo Kenkyusho |
分岐サイクロデキストリンの製造方法
|
US4675332A
(en)
|
1984-12-10 |
1987-06-23 |
Warner-Lambert Company |
Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
|
GB8610981D0
(en)
|
1986-05-06 |
1986-06-11 |
Ici America Inc |
Quinoline amides
|
NZ225045A
(en)
|
1987-07-01 |
1990-06-26 |
Janssen Pharmaceutica Nv |
Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
|
US5002935A
(en)
|
1987-12-30 |
1991-03-26 |
University Of Florida |
Improvements in redox systems for brain-targeted drug delivery
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
BR9106193A
(pt)
|
1990-10-22 |
1993-03-23 |
Bausch & Lomb |
Metodo e composicao para limpar lentes de contato
|
CA2054339C
(en)
|
1990-11-02 |
2002-12-24 |
Francesco G. Salituro |
3-amidoindolyl derivatives
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
US6444221B1
(en)
|
1992-06-30 |
2002-09-03 |
Howard K. Shapiro |
Methods of treating chronic inflammatory diseases using carbonyl trapping agents
|
US20050090553A1
(en)
|
1992-06-30 |
2005-04-28 |
Shapiro Howard K. |
Compositions and method for treatment of chronic inflammatory diseases
|
US5472954A
(en)
|
1992-07-14 |
1995-12-05 |
Cyclops H.F. |
Cyclodextrin complexation
|
TW401300B
(en)
|
1992-12-25 |
2000-08-11 |
Senju Pharma Co |
Antiallergic composition for ophthalmic or nasal use
|
US5493027A
(en)
|
1993-01-22 |
1996-02-20 |
Board Of Regents, The University Of Texas System |
Anticonvulsive agents and uses thereof
|
US5767109A
(en)
|
1993-10-20 |
1998-06-16 |
Sanchez; Robert A. |
Complexing urushiols
|
US5576311A
(en)
|
1994-11-30 |
1996-11-19 |
Pharmos Corporation |
Cyclodextrins as suspending agents for pharmaceutical suspensions
|
JP3297969B2
(ja)
|
1994-12-26 |
2002-07-02 |
ライオン株式会社 |
点眼剤
|
US5597823A
(en)
|
1995-01-27 |
1997-01-28 |
Abbott Laboratories |
Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
|
JP3736916B2
(ja)
|
1996-02-19 |
2006-01-18 |
株式会社サンコンタクトレンズ |
含水性ソフトコンタクトレンズの消毒用組成物とその用途
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
KR20000029694A
(ko)
|
1996-08-01 |
2000-05-25 |
케네쓰 엘. 로에르트셔 |
살진균활성을갖는4-치환된퀴놀린유도체
|
DE69719193T2
(de)
*
|
1996-08-06 |
2003-09-25 |
Pfizer |
Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
|
AU8330898A
(en)
|
1997-05-02 |
1998-11-27 |
Schering Aktiengesellschaft |
Substituted heterocycles and their use in medicaments
|
GB2327672A
(en)
|
1997-07-23 |
1999-02-03 |
Merck & Co Inc |
4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
|
EP1012151B1
(en)
*
|
1997-09-02 |
2002-08-07 |
Bristol-Myers Squibb Pharma Company |
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
|
HUP0102612A2
(hu)
|
1998-03-12 |
2001-11-28 |
Novo Nordisk A/S |
Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
AU1657001A
(en)
|
1999-11-15 |
2001-05-30 |
Smithkline Beecham Corporation |
Carvedilol methanesulfonate
|
WO2001041757A1
(fr)
|
1999-12-10 |
2001-06-14 |
Senju Pharmaceutical Co., Ltd. |
Composition pharmaceutique contenant de la cyclodextrine
|
US6569879B2
(en)
|
2000-02-18 |
2003-05-27 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
JP4748289B2
(ja)
|
2000-06-23 |
2011-08-17 |
ライオン株式会社 |
点眼剤、眼科用組成物及び吸着抑制方法
|
FR2827599A1
(fr)
|
2001-07-20 |
2003-01-24 |
Neuro3D |
Composes derives de quinoleine et quinoxaline,preparation et utilisations
|
UA83620C2
(ru)
|
2001-12-05 |
2008-08-11 |
Уайт |
Замещенные бензоксазолы и их аналоги как эстрогенные агенты
|
US20060014786A1
(en)
|
2002-05-17 |
2006-01-19 |
Rajeev Raut |
Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
US20040198828A1
(en)
|
2003-01-17 |
2004-10-07 |
Abelson Mark B. |
Combinational use of long-acting and short-acting anti-histamines for ocular allergies
|
EP1610772A4
(en)
|
2003-03-14 |
2008-06-18 |
Univ Washington |
RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF
|
US20060111318A1
(en)
|
2003-04-18 |
2006-05-25 |
Advanced Medicine Research Institute |
Agent for treating eye diseases
|
WO2004091630A1
(ja)
|
2003-04-18 |
2004-10-28 |
Advanced Medicine Research Institute |
眼に適用する疾患治療剤
|
US20040235892A1
(en)
|
2003-05-22 |
2004-11-25 |
Yujia Dai |
Indazole and benzisoxazole kinase inhibitors
|
US7297709B2
(en)
|
2003-05-22 |
2007-11-20 |
Abbott Laboratories |
Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
|
US7083803B2
(en)
|
2003-09-19 |
2006-08-01 |
Advanced Ocular Systems Limited |
Ocular solutions
|
JP2005132834A
(ja)
|
2003-10-09 |
2005-05-26 |
Kyowa Hakko Kogyo Co Ltd |
キノリン誘導体
|
TWI344961B
(en)
|
2003-10-15 |
2011-07-11 |
Ube Industries |
Novel indazole derivative
|
EP1678160A1
(en)
|
2003-10-27 |
2006-07-12 |
Astellas Pharma Inc. |
Pyrazine derivatives and pharmaceutical use thereof
|
JP4975440B2
(ja)
|
2003-11-20 |
2012-07-11 |
オセラ・ホールディング・インコーポレイテッド |
黄斑変性およびその他の眼科疾患の改善
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
MXPA06008780A
(es)
|
2004-02-17 |
2007-02-16 |
Harvard College |
Manejo de alteraciones oftalmologicas, incluida la degeneracion macular.
|
US20050234018A1
(en)
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
JP2006008568A
(ja)
|
2004-06-24 |
2006-01-12 |
Cyclochem:Kk |
IgE抗体抑制剤および食品
|
WO2006002473A1
(en)
|
2004-07-02 |
2006-01-12 |
Adelaide Research & Innovation Pty Ltd |
Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
|
FR2875409B1
(fr)
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
JP2008518913A
(ja)
|
2004-10-28 |
2008-06-05 |
メルク エンド カムパニー インコーポレーテッド |
代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子
|
EP1844768A1
(en)
|
2005-01-19 |
2007-10-17 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aromatic sulfone compound as aldosterone receptor modulator
|
TW200640443A
(en)
|
2005-02-23 |
2006-12-01 |
Alcon Inc |
Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
|
US20060257488A1
(en)
|
2005-05-10 |
2006-11-16 |
Cytophil, Inc. |
Injectable hydrogels and methods of making and using same
|
ES2393768T3
(es)
|
2005-05-26 |
2012-12-27 |
Neuron Systems, Inc |
Derivado de quinolina para el tratamiento de enfermedades retinianas
|
US8435965B2
(en)
|
2005-12-27 |
2013-05-07 |
Lion Corporation |
Composition for soft contact lens and adsorption suppressing method
|
US7842312B2
(en)
|
2005-12-29 |
2010-11-30 |
Cordis Corporation |
Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
|
US20070297981A1
(en)
|
2006-01-25 |
2007-12-27 |
Ousler George W Iii |
Formulations and methods for treating dry eye
|
US20070203216A1
(en)
*
|
2006-02-14 |
2007-08-30 |
Bjarke Ebert |
Method of treating inflammatory diseases
|
JP4466875B2
(ja)
|
2006-04-05 |
2010-05-26 |
ライオン株式会社 |
ソフトコンタクトレンズ用点眼剤
|
EP2012789B1
(en)
|
2006-04-14 |
2013-09-25 |
Prana Biotechnology Limited |
Method of treatment of age-related macular degeneration (AMD)
|
JP5194218B2
(ja)
|
2006-06-05 |
2013-05-08 |
株式会社メニコンネクト |
含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
|
CA2658793A1
(en)
|
2006-07-25 |
2008-02-07 |
Daniel Dumas |
Quinoline derivatives
|
JP2010500406A
(ja)
|
2006-08-14 |
2010-01-07 |
シェーリング コーポレイション |
5−(1(s)−アミノ−2−ヒドロキシエチル)−n−[(2,4−ジフルオロフェニル)−メチル]−2−[8−メトキシ−2−(トリフルオロメチル)−5−キノリン]−4−オキサゾールカルボキサミドの塩
|
EP2056792B1
(en)
|
2006-08-31 |
2023-06-07 |
Adare Pharmaceuticals, Inc. |
Drug delivery systems comprising solid solutions of weakly basic drugs
|
US8158609B1
(en)
|
2006-11-02 |
2012-04-17 |
Novartis Ag |
Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
|
US20080241256A1
(en)
|
2007-03-30 |
2008-10-02 |
Liisa Kuhn |
Targeted active agent delivery system based on calcium phosphate nanoparticles
|
WO2008157740A2
(en)
*
|
2007-06-20 |
2008-12-24 |
Ironwood Pharmaceuticals, Inc. |
Faah inhibitors
|
EP2091955B1
(en)
|
2007-10-05 |
2016-12-07 |
Acucela, Inc. |
Alkoxyphenylpropylamines for the treatment of age-related macular degeneration
|
WO2009102418A1
(en)
|
2008-02-11 |
2009-08-20 |
University Of Washington |
Methods for the treatment and prevention of age-related retinal dysfunction
|
CN102177157A
(zh)
|
2008-08-12 |
2011-09-07 |
西特里斯药业公司 |
作为沉默调节蛋白调节剂的苯并*唑类、苯并噻唑类和相关的类似物
|
AU2009308483C1
(en)
|
2008-10-22 |
2014-01-23 |
Acucela, Inc. |
Compounds for treating ophthalmic diseases and disorders
|
JP2012508215A
(ja)
|
2008-11-11 |
2012-04-05 |
ノバルティス アーゲー |
有機化合物
|
WO2010107525A1
(en)
|
2009-03-17 |
2010-09-23 |
Aciex Therapeutics, Inc. |
Ophthalmic formulations of ketotifen and methods of use
|
WO2010133672A1
(en)
|
2009-05-20 |
2010-11-25 |
Clanotech Ab |
Derivatives of quinoline-3-carboxylic acid and their medical use
|
WO2010141834A1
(en)
|
2009-06-05 |
2010-12-09 |
Aciex Therapeutics, Inc. |
Ophthalmic formulations of fluticasone and methods of use
|
US20100331315A1
(en)
|
2009-06-18 |
2010-12-30 |
Mustapha Haddach |
Rhodanines and related heterocycles as kinase inhibitors
|
WO2011008202A1
(en)
|
2009-07-15 |
2011-01-20 |
Vanderbilt University |
Isoketal scavengers and mitigation of disorders involving oxidative injury
|
TWI492769B
(zh)
|
2009-09-23 |
2015-07-21 |
Alcon Res Ltd |
可注射的水性眼用組成物及其使用之方法
|
WO2011071995A2
(en)
|
2009-12-08 |
2011-06-16 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
JP5885670B2
(ja)
|
2009-12-11 |
2016-03-15 |
アルデイラ セラピューティクス, インコーポレイテッド |
黄斑変性の処置のための組成物および方法
|
WO2011078204A1
(ja)
|
2009-12-24 |
2011-06-30 |
浜理薬品工業株式会社 |
高脂血症の予防または治療剤、および抗疲労剤
|
EP3266444A1
(en)
|
2010-02-26 |
2018-01-10 |
Xenon Pharmaceuticals Inc. |
Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
|
US8575221B2
(en)
|
2010-03-17 |
2013-11-05 |
Concert Pharmaceuticals, Inc. |
Derivatives of dimethylcurcumin
|
EP2611782A1
(en)
|
2010-09-01 |
2013-07-10 |
Arena Pharmaceuticals, Inc. |
Salts of lorcaserin with optically active acids
|
WO2012097173A2
(en)
|
2011-01-12 |
2012-07-19 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
WO2012100142A2
(en)
|
2011-01-20 |
2012-07-26 |
Cornell University |
Treatments for retinal disorders
|
EP2670439B1
(en)
|
2011-01-31 |
2019-03-13 |
PVAC Medical Technologies Ltd. |
Active principle for mitigating undesired medical conditions
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
AU2012323952A1
(en)
|
2011-10-13 |
2014-04-24 |
Thomas Gadek |
Topical formulations of chemerin C15 peptides for the treatment of dermatological conditions
|
US20130190500A1
(en)
|
2011-12-12 |
2013-07-25 |
Neuron Systems, Inc. |
Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
|
US20130165419A1
(en)
|
2011-12-21 |
2013-06-27 |
Insite Vision Incorporated |
Combination anti-inflammatory ophthalmic compositions
|
CN104582709A
(zh)
|
2012-08-01 |
2015-04-29 |
路易斯与克拉克药品公司 |
作为a2a激动剂的n-烷基2-(双取代的)炔基腺苷-5’-糖醛酰胺
|
CA2890471C
(en)
|
2012-11-08 |
2021-07-27 |
Clearside Biomedical, Inc. |
Methods and devices for the treatment of ocular diseases in human subjects
|
EP2935220A4
(en)
|
2012-12-20 |
2016-04-27 |
Aldeyra Therapeutics Inc |
PERI-carbinol
|
RU2018145691A
(ru)
|
2013-01-23 |
2019-04-01 |
Альдейра Терапьютикс, Инк. |
Заболевания, связанные с токсичным альдегидом, и их лечение
|
EP2948182B1
(en)
|
2013-01-23 |
2020-09-30 |
Semnur Pharmaceuticals, Inc. |
Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
|
AU2014209585A1
(en)
|
2013-01-25 |
2015-07-23 |
Aldeyra Therapeutics, Inc. |
Novel traps in the treatment of macular degeneration
|
TWI643853B
(zh)
|
2013-02-27 |
2018-12-11 |
阿爾米雷爾有限公司 |
同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
|
US9713330B1
(en)
|
2013-03-15 |
2017-07-25 |
Deuteria Agrochemicals, Llc |
Deuterium-enriched aldehydes
|
WO2015002893A1
(en)
|
2013-07-02 |
2015-01-08 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
US10272106B2
(en)
|
2014-06-04 |
2019-04-30 |
Case Western Reserve University |
Compositions and methods of treating diabetic retinopathy
|
US10736842B2
(en)
|
2014-06-25 |
2020-08-11 |
Synergia Bio Sciences Private Limited |
Pharmaceutical oil-in-water nano-emulsion
|
WO2016018993A1
(en)
|
2014-07-29 |
2016-02-04 |
Therapeuticsmd, Inc. |
Transdermal cream
|
NO2721710T3
(es)
|
2014-08-21 |
2018-03-31 |
|
|
JP2017527614A
(ja)
|
2014-09-02 |
2017-09-21 |
ブピンダー シン |
重水素化又は非重水素化分子及び医薬製剤
|
TW201628622A
(zh)
|
2014-11-17 |
2016-08-16 |
製藥公司 |
Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
|
WO2016085939A2
(en)
|
2014-11-24 |
2016-06-02 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
TWI736531B
(zh)
|
2015-04-15 |
2021-08-21 |
英屬開曼群島商百濟神州有限公司 |
B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途
|
KR20180073553A
(ko)
|
2015-08-21 |
2018-07-02 |
알데이라 테라퓨틱스, 아이엔씨. |
알데히드 접합체 및 이의 용도
|
AU2016311158A1
(en)
|
2015-08-21 |
2018-04-05 |
Aldeyra Therapeutics, Inc. |
Deuterated compounds and uses thereof
|
KR20180116416A
(ko)
|
2016-02-28 |
2018-10-24 |
알데이라 테라퓨틱스, 아이엔씨. |
사이클로덱스트린으로의 알레르기성 안질환의 치료
|
US11129823B2
(en)
|
2016-05-09 |
2021-09-28 |
Aldeyra Therapeutics, Inc. |
Combination treatment of ocular inflammatory disorders and diseases
|
US11865113B2
(en)
|
2016-06-06 |
2024-01-09 |
Lipidio Pharmaceuticals Inc. |
Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)
|
US20180050989A1
(en)
|
2016-08-22 |
2018-02-22 |
Aldeyra Therapeutics, Inc. |
Aldehyde trapping compounds and uses thereof
|
CA3032609A1
(en)
|
2016-08-22 |
2018-03-01 |
Aldeyra Therapeutics, Inc. |
Aldehyde trapping compounds and methods of use thereof
|
AU2017336765B2
(en)
|
2016-09-28 |
2023-06-08 |
Medicon Pharmaceuticals, Inc. |
Compositions and methods for treating ophthalmic conditions
|
LT3523283T
(lt)
|
2016-10-05 |
2021-07-12 |
Mitobridge, Inc. |
Ppar agonistų junginių kristalinės ir druskos formos
|
WO2018170476A1
(en)
|
2017-03-16 |
2018-09-20 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
AU2018348174A1
(en)
|
2017-10-10 |
2020-04-23 |
Aldeyra Therapeutics, Inc. |
Treatment of inflammatory disorders
|
WO2020018498A1
(en)
|
2018-07-16 |
2020-01-23 |
Aldeyra Therapeutics, Inc. |
Cyclodextrin formulations
|
US20200038392A1
(en)
|
2018-08-03 |
2020-02-06 |
Aldeyra Therapeutics, Inc. |
Topical compositions and methods of preparation and use
|
EP3833660A4
(en)
|
2018-08-06 |
2022-05-11 |
Aldeyra Therapeutics, Inc. |
POLYMORPHIC COMPOUNDS AND THEIR USES
|
CN115869258A
(zh)
|
2018-09-25 |
2023-03-31 |
奥尔德拉医疗公司 |
用于治疗干眼病的调配物
|
US20210317385A1
(en)
|
2018-10-02 |
2021-10-14 |
Aldeyra Therapeutics, Inc. |
Contact lens solutions and kits
|
EP3890732A4
(en)
|
2018-12-05 |
2022-08-24 |
Aldeyra Therapeutics, Inc. |
INJECTABLE FORMULATIONS
|
US11786518B2
(en)
|
2019-03-26 |
2023-10-17 |
Aldeyra Therapeutics, Inc. |
Ophthalmic formulations and uses thereof
|
WO2020223717A1
(en)
|
2019-05-02 |
2020-11-05 |
Aldeyra Therapeutics, Inc. |
Process for preparation of aldehyde scavenger and intermediates
|
CA3137301A1
(en)
|
2019-05-02 |
2020-11-05 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
US20230131929A1
(en)
|
2020-03-24 |
2023-04-27 |
Aldeyra Therapeutics, Inc. |
Quinoline compounds for treating respiratory disorders and viral infections
|
WO2021211625A1
(en)
|
2020-04-13 |
2021-10-21 |
Aldeyra Therapeutics, Inc. |
Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
|
JP2023526016A
(ja)
|
2020-05-13 |
2023-06-20 |
アルデイラ セラピューティクス, インコーポレイテッド |
医薬製剤およびその使用
|
US20230228744A1
(en)
|
2020-06-04 |
2023-07-20 |
Aldeyra Therapeutics, Inc. |
Dry eye disease biomarkers and their use for treatment
|
WO2022150580A1
(en)
|
2021-01-07 |
2022-07-14 |
Aldeyra Therapeutics, Inc. |
Treatment of dry eye disease
|
US20220211691A1
(en)
|
2021-01-07 |
2022-07-07 |
Aldeyra Therapeutics, Inc. |
Treatment of dry eye disease
|